When the Signal From Phase 2 Research Should Be a Warning Sign
Mené sur 87 patients atteints d'un cancer du poumon non à petites cellules présentant la mutation T790M du gène EGFR (âge médian : 68 ans), cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du bévacizumab à l'osimertinib, après l'échec de traitements par inhibiteurs de tyrosine kinase de l'EGFR
The article by Akamatsu and colleagues1 in this issue of JAMA Oncology describes a phase 2 randomized clinical trial that tests the value of adding the vascular endothelial growth factor inhibitor bevacizumab to osimertinib in 81 Japanese patients with EGFR mutation–positive advanced non–small cell lung cancer (NSCLC) and T790M mutation–positive acquired resistance on a prior epidermal growth factor receptor (EGFR) inhibitor. In contrast with what many of us may have expected, the data revealed no hint of a favorable signal for progression-free survival (PFS) or overall survival (OS) with the combination.
JAMA Oncology , éditorial en libre accès, 2020